These two offerings combined will bring in about $1.1B of cash, if priced at close to the current market value. The cash portion (~70%) of the Bayer deal is $5.3B (#msg-150629685).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”